Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 UB-312 immunotherapeutic vaccine study in healthy adults and participants with Parkinson's disease
NL-OMON54871Phase 1Active, not recruiting
- Sponsor
- Vaxxinity
- Start
- Aug 2019
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of ub-312 in Parkinson's disease (PD) (2 arms), sponsored by Vaxxinity. Primary endpoints: Safety and tolerability and Immunogenicity in blood and cerebrospinal fluid. Started Aug 2019; status: active, not recruiting.
02
Drugs
ub-312
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON54871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54871.